Audacious Alpha™
Leveraging proprietary zwitterionic technology to deliver best-in-class outcomes for targeted alpha therapy (TAT).
Leveraging proprietary zwitterionic technology to deliver best-in-class outcomes for targeted alpha therapy (TAT).
Bringing “cure” into the cancer conversation.
Curadel Pharma is an audacious innovator aiming to prevent tumor resistance via disruptive zwitterionic radiopharma technology. Our novel, pan-tumor platform prevents tumor regrowth and resistance while eliminating collateral damage to healthy tissues.
As pioneers of the next generation of radiopharma, we aim to redefine long-term outcomes for people with challenging metastatic cancers.
Our Audacious Science.
Our Founder is a pioneer in zwitterionicity, a novel and well validated concept to improve the therapeutic window and reduce the collateral damage associated with state-of-the-art targeted alpha therapies (TATs). Learn more about our proprietary therapeutic strategy.
View FDA Expanded Access Policy here.
Curadel Pharma Initiates Phase 3 Trial of ZW800-1, a First-in-class Zwitterionic Drug for Optical Surgical Navigation
Curadel Pharma, a pioneer in zwitterionicity and innovator in advanced radiotherapies and drugs for optical surgical navigation, announced today that it has initiated the Phase 3 portion of its pivotal study evaluating the investigational ZW800-1 (nizaracianine triflutate) to highlight the ureter during abdominopelvic surgery.
Curadel Pharma secures $10.5M in series A2 funding to propel novel Zwitterionic Radiotherapy Platform
Curadel Pharma, a pioneer in zwitterionicity and innovator in advanced radiotherapies and imaging drugs, announced completion of a Series A2 funding round, securing $10.5M to advance early stage development for its lead programs.